Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis
Author:
Publisher
Informa UK Limited
Subject
Oncology
Reference38 articles.
1. Breast Cancer Metastasis: Challenges and Opportunities
2. Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
3. How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials
4. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype
5. Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting;Breast Cancer Research and Treatment;2024-06-26
2. Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2− Metastatic Breast Cancer;Cancers;2024-06-07
3. A systematic literature review on direct and indirect costs of triple-negative breast cancer;Cost Effectiveness and Resource Allocation;2023-11-30
4. Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States;Breast Cancer Research and Treatment;2023-01-07
5. The impact of geographical and sociodemographic variation on access to Systemic Anti- Cancer Therapies for Secondary Breast Cancer: A systematic review;2022-10-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3